Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study | Zendy

Francesco Locatelli | Zendy; Nada Dimković | Zendy; Giuseppe Pontoriero | Zendy; Goce Spasovski | Zendy; S. Plješa | Zendy; S. Kostić | Zendy; A Manning | Zendy; Hiroyuki Sano | Zendy; S. Nakajima | Zendy

Open Access

Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study

Author(s) -

Francesco Locatelli,

Nada Dimković,

Giuseppe Pontoriero,

Goce Spasovski,

S. Plješa,

S. Kostić,

A Manning,

Hiroyuki Sano,

S. Nakajima

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp445

Subject(s) - medicine , placebo , hemodialysis , double blind , phosphate binder , sevelamer , phosphate , randomized controlled trial , cholesterol , gastroenterology , double blind study , urology , hyperphosphatemia , kidney disease , pathology , alternative medicine , chemistry , organic chemistry

Hyperphosphataemia in patients on haemodialysis (HD) can lead to, or worsen, secondary hyperparathyroidism (with associated bone disease) and extra-skeletal calcifications associated with increased cardiovascular morbidity and mortality. MCI-196 is a new, non-absorbed, non-calcium-based phosphate binder. The aim of this study was to determine the effect of three fixed doses of MCI-196, on serum phosphorus level and other parameters relevant to HD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research